407. Papillary thyroid cancer: Treatment strategies and prognostic factors at the Instituto Português de Oncologia do Porto

2016 ◽  
Vol 42 (9) ◽  
pp. S161
Author(s):  
M. Peyroteo ◽  
A. Sousa ◽  
A. Ferreira ◽  
C. Ribeiro ◽  
A. Mesquita ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Prognostic Factors ◽  
Cancer Treatment ◽  
Papillary Thyroid Cancer ◽  
Treatment Strategies ◽  
Papillary Thyroid

scholarly journals Long-term Results of Papillary Thyroid Cancer Treatment and Comparative Analisis of Various Treatment Strategies

2014 ◽  
Vol 10 (1) ◽  
pp. 31-37
Author(s):  
R A Chernikov ◽  
E A Valdina ◽  
S L Vorobjev ◽  
I V Sleptsov ◽  
A A Semenov ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Treatment ◽  
Papillary Thyroid Cancer ◽  
Treatment Strategies ◽  
Long Term Results ◽  
Papillary Thyroid

scholarly journals The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors

PLoS ONE ◽  
2015 ◽  
Vol 10 (7) ◽  
pp. e0132821 ◽  
Author(s):  
Agnieszka Czarniecka ◽  
Monika Kowal ◽  
Dagmara Rusinek ◽  
Jolanta Krajewska ◽  
Michal Jarzab ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Prognostic Factors ◽  
Papillary Thyroid Cancer ◽  
Papillary Thyroid ◽  
Brafv600e Mutation ◽  
Mutation Status ◽  
Risk Of Relapse

scholarly journals Correlation between F18-FDG PET/CT Imaging and BRAF V600E Genetic Mutation for the Early Assessment of Treatment Response in Papillary Thyroid Cancers

2020 ◽  
Vol 10 (2) ◽  
pp. 52
Author(s):  
Andra Piciu ◽  
Maria-Iulia Larg ◽  
Doina Piciu
Keyword(s):  
Thyroid Cancer ◽  
Prognostic Factors ◽  
Papillary Thyroid Cancer ◽  
Genetic Mutation ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Papillary Thyroid ◽  
Early Assessment ◽  
Pet Ct ◽  
Ct Evaluation

In thyroid neoplastic pathology, the BRAF V600E mutation is shown to be involved in the oncogenesis of papillary thyroid cancer and its subtypes. The purpose of this study is to evaluate the correlation between the mutation of the BRAF V600E oncogene and the pathological standardized uptake values (SUV) at the F18-fluorodeoxyglucose (F18-FDG) positron emission tomography/computed tomography (PET/CT) evaluation, for a group of 20 patients with radically treated (total thyroidectomy and radioiodine therapy) papillary thyroid cancer, with subclinical persistent disease, at 6 months after the initial treatment. We analyzed the correlations between the values of SUV and the presence of the BRAF mutation as well with other prognostic factors such as stage, age, specific tumor markers (thyroglobulin and anti-thyroglobulin), extrathyroid extension, the presence of metastatic lymph nodes or distant metastasis. The value of SUV in the case of BRAF+ (positive) patients was higher than in the negative ones, but without statistical significance, thus, the values of the SUV cannot be a predictable factor for the presence of the genetic mutation. There was a statistically significant correlation in BRAF+ subgroup between the SUV values and the positive resection limit following surgery, showing a higher SUV value in the PET/CT evaluation. No correlation was observed between the aforementioned prognostic factors involved in papillary thyroid cancer and the BRAF V600E mutation.

scholarly journals Successful Treatment by Surgery and Lenvatinib of a Patient with Adrenal Metastasis of Papillary Thyroid Cancer

2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Hajime Nakamura ◽  
Kohichi Takada ◽  
Kazuyuki Murase ◽  
Hiroki Sakamoto ◽  
Naotaka Hayasaka ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Adverse Events ◽  
Papillary Thyroid Cancer ◽  
Surgical Resection ◽  
Tyrosine Kinases ◽  
Treatment Strategies ◽  
Stable State ◽  
Adrenal Metastasis ◽  
Papillary Thyroid ◽  
Serious Adverse Events

Papillary thyroid cancer (PTC) is considered an indolent cancer, but some PTC patients do present with distant metastases and treatment strategies for such patients are not well established. Recently, lenvatinib, an inhibitor of multiple tyrosine kinases, has been introduced to treat patients with advanced PTC but carries a risk of serious adverse events such as hemorrhage. Here, we report a PTC patient with a left adrenal metastasis and lenvatinib-induced hemorrhage who underwent successful surgical resection and was subsequently treated with a lower dose of lenvatinib. The patient has now been in a stable state with no adverse events for nearly two years. This case highlights the importance of surgical resection of metastatic PTC and subsequent lenvatinib therapy, even when the tumor is at an advanced stage.

scholarly journals Annual Hazard Rate of Recurrence in Middle Eastern Papillary Thyroid Cancer over a Long-Term Follow-Up

Cancers ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3624
Author(s):  
Abdul K. Siraj ◽  
Sandeep Kumar Parvathareddy ◽  
Zeeshan Qadri ◽  
Khawar Siddiqui ◽  
Saif S. Al-Sobhi ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Hazard Rate ◽  
Tumor Recurrence ◽  
Cox Regression ◽  
Middle Eastern ◽  
Treatment Strategies ◽  
Recurrence Risk ◽  
Papillary Thyroid ◽  
Cox Regression Analysis

Predicting the pattern of recurrence in papillary thyroid cancer (PTC) is necessary to establish optimal surveillance and treatment strategies. We analyzed changes in hazard rate (HR) for tumor recurrence over time in 1201 unselected Middle Eastern PTC patients. The changes in risk were further analyzed according to clinical variables predictive of early (≤5 years) and late (>5 years) recurrence using Cox regression analysis to identify patient populations that remain at risk. Tumor recurrence was noted in 18.4% (221/1201) patients. The annualized hazard of PTC recurrence was highest during the first 5 years (2.8%), peaking between 1 and 2 years (3.7%), with a second smaller peak between 13 and 14 years (3.2%). Patients receiving radioactive iodine (RAI) therapy had lower recurrence hazard compared to those who did not (1.5% vs. 2.7%, p = 0.0001). Importantly, this difference was significant even in intermediate-risk PTC patients (0.7% vs. 2.3%; p = 0.0001). Interestingly, patients aged ≥55 years and having lymph node metastasis were at persistent risk for late recurrence. In conclusion, we confirmed the validity of the double-peaked time-varying pattern for recurrence risk in Middle Eastern PTC patients and our findings could help in formulating individualized treatment and surveillance plans.

Prognostic Factors in Papillary Thyroid Cancer: An Evaluation of 601 Consecutive Patients

Tumor Biology ◽  
2005 ◽  
Vol 26 (2) ◽  
pp. 57-64 ◽  
Author(s):  
Päivi Siironen ◽  
Johanna Louhimo ◽  
Stig Nordling ◽  
Ari Ristimäki ◽  
Hanna Mäenpää ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Prognostic Factors ◽  
Papillary Thyroid Cancer ◽  
Papillary Thyroid
Sign in / Sign up

Export Citation Format

Share Document